Molina Healthcare (MOH) shares have seen a mix of ups and downs recently. The share price witnessed an upward trajectory after positive sector-wide news sparked by Berkshire's stake. However, concerns over MOH's capability to sustain exchange segment margins amidst medical cost pressures, led to market reservations. A suspected fraud probe has further plunged the company under scrutiny, but Wells Fargo maintains an overweight rating despite price target adjustment from $216 to $198. A senior EVP & COO's 16% shares purchase boosted investor's confidence, whilst negative forecasts from Zacks Research hints at a precarious earning situation. The company has also announced preliminary Q2 financial results with fiscal year 2025 EPS guidance updates. Key developments within the firm include signing of CEO Joe Zubretsky to a new employment agreement, and expanding CFO Mark Keim's role. Acquisition developments, with MOH's plan to buy ConnectiCare and Cignaβs Texas Medicaid Contracts, added to the market excitement. The future outlook remains cloudy due to technical weakness and mixed analyst views, despite optimism around MOH's multi-year premium revenue.
Molina Healthcare MOH News Analytics from Thu, 22 Apr 2021 07:00:00 GMT to Sat, 16 Aug 2025 06:37:57 GMT -
Rating 1
- Innovation -2
- Information 3
- Rumor -5
